ArticleJTO clinical and research reports2023

Real-World Immunotherapy Use and Effectiveness in Advanced NSCLC With Programmed Death-Ligand 1 Greater Than or Equal to 50% and Greater Than or Equal to 90.

Ashley Jackson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.